If you have any other questions or need other size, please get a quote.
The molecular formula of acalabrutinib is C26H23N7O2.
The molecular weight of acalabrutinib is 465.5 g/mol.
Acalabrutinib was created on March 21, 2013, and last modified on December 30, 2023.
Acalabrutinib is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Acalabrutinib is a member of the class of imidazopyrazines.
The mechanism of action of acalabrutinib is as a Tyrosine Kinase Inhibitor.
Acalabrutinib has been studied for the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma.
Yes, a new tablet formulation of acalabrutinib has been approved by the FDA, enabling co-administration with proton pump inhibitors (PPIs).
Acalabrutinib has received Priority Review, Breakthrough Therapy, and Orphan Drug designations from the FDA.
More than 35 clinical trials across 40 countries with more than 2500 patients have been conducted with acalabrutinib.
762240-92-6
87885-43-6
940-07-8
1458-01-1
1254053-43-4
1589527-65-0
Discover More
Chemical Fluorescence Probe
Dyes
Fluorinated Building Blocks
Heterocyclic Organic Compound
Insect Pheromone
Ionic Liquids
Lipid Compounds
Main Products
Contact Us
For product inquiries, please use our online system or send an email to .